IR@PKUHSC  > 北京大学基础医学院
学科主题基础医学
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation
Dong, Shuying1; Kong, Jian1; Kong, Fandong5,6; Kong, Jinge5,6; Gao, Jun1; Ji, Liang2,3,4; Pan, Bing2,3,4; Chen, Lian7; Zheng, Lemin2,3,4; Sun, Wenbing1
关键词Hepatocellular carcinoma Insufficient radiofrequency ablation Epithelial-mesenchymal transition Sorafenib
刊名BMC CANCER
2015-11-30
DOI10.1186/s12885-015-1949-7
15
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者Dr. Jieping Wu Medical Foundation ; Program for Medical Key Discipline of Shijingshan District, Beijing ; "973" National ST Major Project ; National Natural Science Foundation of China ; Natural Science Foundation of Beijing, China ; Dr. Jieping Wu Medical Foundation ; Program for Medical Key Discipline of Shijingshan District, Beijing ; "973" National ST Major Project ; National Natural Science Foundation of China ; Natural Science Foundation of Beijing, China
研究领域[WOS]Oncology
关键词[WOS]RAPID PROGRESSION ; PATHWAYS ; CHEMOEMBOLIZATION ; METASTASIS ; INHIBITION ; THERAPY ; CANCER
英文摘要

Background: Epithelial-mesenchymal transition (EMT) played an important role in the progression of hepatocellular carcinoma (HCC) after insufficient radiofrequency ablation (RFA). However, whether sorafenib could be used to suppress the EMT of HCC after insufficient RFA and further prevent the progression of residual HCC remains poorly unknown.

Methods: Insufficient RFA was simulated using a water bath (47 degrees C 5, 10, 15, 20 and 25 min gradually). MTT assay and transwell assay were used to evaluate the effects of sorafenib on viability, migration and invasion of HepG2 and SMMC7721 cells after insufficient RFA in vitro. After insufficient RFA, the molecular changes in HCC cells with the treatment of sorafeinb were evaluated using western blot and ELISAs. An ectopic nude mice model was used to evaluate the effect of sorafenib on the growth of HepG2 cells in vivo after insufficient RFA.

Results: HepG2 and SMMC7721 cells after insufficient RFA (named as HepG2-H and SMMC7721-H) exhibited enhanced viability, migration and invasion in vitro. Sorafenib inhibited the enhanced viability, migration and invasion of HepG2 and SMMC7721 cells after insufficient RFA. Molecular changes of EMT were observed in HepG2-H and SMMC7721-H cells. Sorafenib inhibited the EMT of HepG2-H and SMMC7721-H cells. HepG2-H cells also exhibited larger tumor size in vivo. Higher expression of PCNA, Ki67, N-cadherin, MMP-2 and MMP-9, was also observed in HepG2-H tumors. Sorafenib blocked the enhanced growth of HepG2 cells in vivo after insufficient RFA.

Conclusions: Sorafenib inhibited the EMT of HCC cells after insufficient RFA, and may be used to prevent the progression of HCC after RFA.

语种英语
所属项目编号320675007131 ; 32067501207 ; 2011CB503900 ; 81170101 ; 81370235 ; 81572957 ; 81502650 ; 7122106
资助者Dr. Jieping Wu Medical Foundation ; Program for Medical Key Discipline of Shijingshan District, Beijing ; "973" National ST Major Project ; National Natural Science Foundation of China ; Natural Science Foundation of Beijing, China ; Dr. Jieping Wu Medical Foundation ; Program for Medical Key Discipline of Shijingshan District, Beijing ; "973" National ST Major Project ; National Natural Science Foundation of China ; Natural Science Foundation of Beijing, China
WOS记录号WOS:000365490400001
Citation statistics
Cited Times:5[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63140
Collection北京大学基础医学院
作者单位1.Capital Med Univ, Beijing Chao Yang Hosp, Dept Hepatobiliary Surg, Beijing 100043, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Beijing 100191, Peoples R China
3.Peking Univ, Hlth Sci Ctr, Key Lab Mol Cardiovasc Sci, Minist Educ,Inst Cardiovasc Sci, Beijing 100191, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Inst Syst Biomed, Beijing 100191, Peoples R China
5.Peking Univ, Neurosci Res Inst, Sch Basic Med Sci, Dept Neurobiol, Beijing 100191, Peoples R China
6.Peking Univ, Natl Hlth & Family Planning Commiss, Minist Educ, Key Lab Neurosci, Beijing 100191, Peoples R China
7.Fujian Med Univ, Affiliated Mindong Hosp, Dept Orthopaed 8, Fuzhou 355000, Fujian, Peoples R China
Recommended Citation
GB/T 7714
Dong, Shuying,Kong, Jian,Kong, Fandong,et al. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation[J]. BMC CANCER,2015,15.
APA Dong, Shuying.,Kong, Jian.,Kong, Fandong.,Kong, Jinge.,Gao, Jun.,...&Sun, Wenbing.(2015).Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.BMC CANCER,15.
MLA Dong, Shuying,et al."Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation".BMC CANCER 15(2015).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Dong, Shuying]'s Articles
[Kong, Jian]'s Articles
[Kong, Fandong]'s Articles
百度学术
百度学术Similar articles in
[Dong, Shuying]'s Articles
[Kong, Jian]'s Articles
[Kong, Fandong]'s Articles
必应学术
必应学术Similar articles in
[Dong, Shuying]'s Articles
[Kong, Jian]'s Articles
[Kong, Fandong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.